Information for site staff
Every COVID-19 patient in the UK may be invited to participate in the RECOVERY Trial. Randomisation is currently to one of these arms: usual care; usual care plus low-dose dexamethasone (now only recruiting children); usual care plus azithromycin, a commonly used antibiotic; usual care plus convalescent plasma (collected from donors who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus). There is a second randomisation for participants who deteriorate between tocilizumab and control. The trial is designed to have the least possible impact on NHS staff. You will find Frequently Asked Questions on the site set-up page.
See Update Alert on this page for update details.
29 June 2020
Lopinavir-ritonavir arm of the RECOVERY Trial
The lopinavir-ritonavir arm of RECOVERY closed to new randomisations on 29th June. The preliminary analyses have been reported today, for full information see the statement on the results page. We would recommend that participants currently taking lopinavir-ritonavir stop.
17 june 2020
Any trial stocks of hydroxychloroquine or dexamethasone that you have left over may be used for “business as usual” supplies. This means that you can use the dexamethasone to treat patients requiring oxygen for COVID (as stated in the CAS alert issued yesterday). The hydroxychloroquine can be used for its licensed indications.
16 June 2020
Dexamethasone arm of the RECOVERY Trial
The dexamethasone arm of RECOVERY closed to new randomisations on 8th June. The preliminary analyses have today been reported, for full information see the press release on the results page. Randomisation of children into the dexamethasone arm of the trial will continue.
The RECOVERY Trial protocol is available for use by investigators everywhere to design their own randomised trials that could help identify effective treatments for COVID-19.